Dr Rodrigo Motta Guerrero discusses his ecancermedicalscience journal article 'Targeting BRAF V600E in metastatic colorectal cancer: where are we today?'.
He outlines that BRAF V600E metastatic colorectal cancer patients are usually associated with poor prognosis resulting in poor overall survival which is why they decided to conduct a review into the treatment options currently available.
Dr Guerrero explains the key findings of this review showed immunotherapy, the combination of BRAF and EGFR inhibitors and the combination of chemotherapy with angiogenic inhibitors have managed to prolong the survival of this patient population.
He concludes by highlighting how these review results might impact future research into metastatic colorectal cancer with BRAF V600E mutations.
Read the full study here